Johan Devenyns

As former CEO of a peptide and oligonucleotide CDMO business and former CEO of PharmaFluidics, an omics research tools business, Johan brings a broad international experience in innovative life sciences industries. He lead a variety of fundraisings, M&A and successful exits.

Besides his role at LiveDrop, he serves in different board and advisory roles, supporting life sciences ventures in various stages of creation & growth.

Johan holds a PhD in biomaterials, MBA and is a certified board director.

He said : "The overarching trend in therapeutic modalities and the pharmaceutical industry has been a progression from small molecule drugs (pre-1990s), through categories like peptides and nucleotides (from 1990s onwards), over biologicals such as proteins and mAbs (last decades). We are now witnessing a tectonic shift towards cell therapy, often administered in personalised formats.

There is no doubt that the ability to study the biology and interaction of cells at individual or small cluster level, at large scale, is of paramount importance; LiveDrop stands ready to facilitate this life-saving journey."